Neoplasia (New York, N.Y.) - JoVE Visualize

Showing results (1071-1080 of 2,753) with videos related to

Pageof 276

Sort By:

Neoplasia (New York, N.Y.)|January 26, 2020

AGO2 phosphorylation by c-Src kinase promotes tumorigenesisTianqi Liu, Hailong Zhang, Jiayu Fang, et al.

Neoplasia (New York, N.Y.)|March 27, 2015

JAK kinase inhibition abrogates STAT3 activation and head and neck squamous cell carcinoma tumor growthMalabika Sen, Netanya I Pollock, John Black, et al.

Neoplasia (New York, N.Y.)|March 27, 2015

ABCG2 localizes to the nucleus and modulates CDH1 expression in lung cancer cellsShu-Ching Liang, Chih-Yung Yang, Ju-Yu Tseng, et al.

Neoplasia (New York, N.Y.)|March 10, 2015

Erlotinib-cisplatin combination inhibits growth and angiogenesis through c-MYC and HIF-1α in EGFR-mutated lung cancer in vitro and in vivoJasmine G Lee, Reen Wu

Neoplasia (New York, N.Y.)|April 14, 2023

Hepatocellular carcinoma-derived FOXO1 inhibits tumor progression by suppressing IL-6 secretion from macrophagesXiao Cui, Huiyong Zhao, Sheng Wei, et al.

Neoplasia (New York, N.Y.)|May 12, 2023

Nuclear morphology predicts cell survival to cisplatin chemotherapyChi-Ju Kim, Anna Lk Gonye, Kevin Truskowski, et al.

Neoplasia (New York, N.Y.)|May 6, 2023

Targeting MYC in combination with epigenetic regulators induces synergistic anti-leukemic effects in MLLr leukemia and simultaneously improves immunityRahel Fitzel, Kathy-Ann Secker-Grob, Hildegard Keppeler, et al.

Neoplasia (New York, N.Y.)|January 10, 2014

Supplementation of nicotinic acid with NAMPT inhibitors results in loss of in vivo efficacy in NAPRT1-deficient tumor modelsThomas O'Brien, Jason Oeh, Yang Xiao, et al.

Neoplasia (New York, N.Y.)|January 10, 2014

Inflammatory factors of the tumor microenvironment induce plasticity in nontransformed breast epithelial cells: EMT, invasion, and collapse of normally organized breast texturesTal Leibovich-Rivkin, Yulia Liubomirski, Biana Bernstein, et al.

Neoplasia (New York, N.Y.)|January 10, 2014

Quantitative analysis of [11C]-erlotinib PET demonstrates specific binding for activating mutations of the EGFR kinase domainJ Ryan Petrulli, Jenna M Sullivan, Ming-Qiang Zheng, et al.

Pageof 276

Showing results (1071-1080 of 2,753) with videos related to

Sort By:

Pageof 276

Neoplasia (New York, N.Y.)|January 26, 2020

AGO2 phosphorylation by c-Src kinase promotes tumorigenesisTianqi Liu, Hailong Zhang, Jiayu Fang, et al.

Neoplasia (New York, N.Y.)|March 27, 2015

JAK kinase inhibition abrogates STAT3 activation and head and neck squamous cell carcinoma tumor growthMalabika Sen, Netanya I Pollock, John Black, et al.

Neoplasia (New York, N.Y.)|March 27, 2015

ABCG2 localizes to the nucleus and modulates CDH1 expression in lung cancer cellsShu-Ching Liang, Chih-Yung Yang, Ju-Yu Tseng, et al.

Neoplasia (New York, N.Y.)|March 10, 2015

Erlotinib-cisplatin combination inhibits growth and angiogenesis through c-MYC and HIF-1α in EGFR-mutated lung cancer in vitro and in vivoJasmine G Lee, Reen Wu

Neoplasia (New York, N.Y.)|April 14, 2023

Hepatocellular carcinoma-derived FOXO1 inhibits tumor progression by suppressing IL-6 secretion from macrophagesXiao Cui, Huiyong Zhao, Sheng Wei, et al.

Neoplasia (New York, N.Y.)|May 12, 2023

Nuclear morphology predicts cell survival to cisplatin chemotherapyChi-Ju Kim, Anna Lk Gonye, Kevin Truskowski, et al.

Neoplasia (New York, N.Y.)|May 6, 2023

Targeting MYC in combination with epigenetic regulators induces synergistic anti-leukemic effects in MLLr leukemia and simultaneously improves immunityRahel Fitzel, Kathy-Ann Secker-Grob, Hildegard Keppeler, et al.

Neoplasia (New York, N.Y.)|January 10, 2014

Supplementation of nicotinic acid with NAMPT inhibitors results in loss of in vivo efficacy in NAPRT1-deficient tumor modelsThomas O'Brien, Jason Oeh, Yang Xiao, et al.

Neoplasia (New York, N.Y.)|January 10, 2014

Inflammatory factors of the tumor microenvironment induce plasticity in nontransformed breast epithelial cells: EMT, invasion, and collapse of normally organized breast texturesTal Leibovich-Rivkin, Yulia Liubomirski, Biana Bernstein, et al.

Neoplasia (New York, N.Y.)|January 10, 2014

Quantitative analysis of [11C]-erlotinib PET demonstrates specific binding for activating mutations of the EGFR kinase domainJ Ryan Petrulli, Jenna M Sullivan, Ming-Qiang Zheng, et al.

Pageof 276